@SaurabhVj My bad; you are right. It has started from 28/12/2023 and that means it should have been in the pf. This week I have already completed my rebalancing. Will be in contention next week.
Thanks for highlighting.
@SaurabhVj My bad; you are right. It has started from 28/12/2023 and that means it should have been in the pf. This week I have already completed my rebalancing. Will be in contention next week.
Thanks for highlighting.
Hi @visuarchie ,
Azad listed on 28/12/2023. It has completed 6 months now right or are you talking about 6 months of trading sessions(180 trading sessions)?
It is because, Company avails Remission of Duties and Taxes on Exported Products (RODTEP) & Duty Drawback grants.
Portfolio update
NAME OF COMPANY | CMP 01-07-2024 | Allocation | UNREALISED GAIN | |
---|---|---|---|---|
AVG INVST PRICE | ||||
SRG Housing Finance | 204.28 | 338.30 | 27.8% | 65.6% |
Punjab Chemicals | 772.45 | 1,436.75 | 24.3% | 86.0% |
Mitsu | 150.23 | 141.90 | 6.2% | -5.5% |
Innova Captab | 499.09 | 506.15 | 6.6% | 1.4% |
IRM Energy | 537.21 | 463.20 | 5.7% | -13.8% |
Prevest Denpro | 377.47 | 550.00 | 4.3% | 45.7% |
Prime Fresh | 202.82 | 203.00 | 5.0% | 0.1% |
CASH | - | 20.1% | 0.0% |
Planning to sell IRM Energy as promoter is not minority investor friendly
Planning to reduce Mitsu to half as I’m not sure about promoter capability
How did you get the Best Case and Worst Case scenarios in Screener?
Thanks for this Kushal,
Very nice analysis.
If I am not mistaken, I have seen they are affected by “Holi” before as well.
Who are BIGBLOC’s main competitors?
Disc: Invested
That sounds like a well-defined strategy. Using technical charts for entry and having a clear exit point can help maintain discipline. Chart Ink screeners are a good tool for identifying potential stocks. Have you found any particular technical indicators or patterns to be more reliable for your entries?
There seems to be lot of infighting going in the family.
Anyone tracking it.
Disc : Not invested
NATCO Pharma Ltd
NATCO (established in 1981) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. The company growth story is due to its strong R&D focus and product pipelines. The co is projected to give returns of 94% next year
Date of report: | 24-06-2024 | Industry PE | 33.08 | Sector | Pharmaceuticals |
---|---|---|---|---|---|
CMP: | 1196 | Current PE | 15.43 | No of Years | 43 |
Market Cap: | 21416Cr | Highest PE | 73.7 (2022) | Key Products | Complex Formula |
ROCE / ROE | 30% / 25.9% | Lowest PE | 3.1 (2008) | Key Competitor | Biocon Ltd |
Business Model and Industry Analysis
Overview:
The company can be divided into 4 sectors namely Domestic Formulation, Export Formulation, Crop Health Science and Active Pharmaceutical Ingredients (API).
Industry Growth:
The US pharma market is expected to grow at 5.36% CAGR. The pharmerging market is expected to grow at 8.97% CAGR where the company is trying to expand its customer base and introduce new products. The API market is expected to grow at CAGR of 7.22%. Further higher spending capacity and increasing diseases among population supports NATCO’s business.
Capacity Utilisation:
Co has 5 FDF manufacturing facility, 2 API manufacturing facility, 2 R&D centres and 2 crop health science units. The company has major concentration with exception of 2 facilities in Uttarakhand and Assam. Company has no huge capacity plans thus it can be assumed that this plants has spare capacity to support future growth
Opportunities:
Risk:
Future Expansion:
The company do not have any committed future expansion plans. It will be looking out for opportunities for inorganic acquisition which helps to either enter new geographies or new molecule segment
Management:
Management has delivered its commitment and is focused on core business operations. Further there are no much related party transactions. Promoters hold 49.7% shares which are free from any pledge
Institutional Investor:
FII and DII continue to hold around 26% in the company
Historical Data and Financials
Profit N Loss Account:
* Sales have historically grown at **18%** CAGR over last 10 years and at **48%** in last year
* Margins have continuously improved and stands at around **44%** currently
Balance Sheet:
* Company has high net cash which it is holding for inorganic growth opportunities
* Interest coverage ratio is **91 times**
* EVA of company is positive
* Inventory days have reduced from **432** days to **357** days
* Debtor days is constant
* Working Cycle and Cash conversion cycle have improved YoY
* Current ratio stands at 8 times.
Cash Flow:
* CFO/PAT is at lower side standing at 88.58% due to long working capital cycle
* It is a cash rich company and can support acquisition through internal accruals
Valuation and future potential:
Particular | Current | 52W High | 52W Low | Historical High | Historical Low | Industry Median |
---|---|---|---|---|---|---|
Price | 1196 | 1210 | 671 | 1210 | 9.1 | - |
PE Ratio | 15.43 | 22.4 | 12.1 | 73.7 | 3.1 | 33.08 |
EPS | 77.51 | 77.51 | 45.1 | 77.51 | 2.1 | - |
Price/Book | 3.7 | 3.9 | 2.5 | 14.4 | 0.6 | 3.62 |
EV/EBITDA | 11.1 | 15.3 | 8.6 | 44.1 | 0.9 | 18.18 |
Valuation:
Particular | 23/24 | 24/25 | Comments |
---|---|---|---|
Sales | 3999 | 4798 | Management Conservative guidance |
Profit | 1388 | 1665 | Management Conservative guidance |
No of Share | 17.9 | 17.9 | - |
EPS | 77.51 | 93.02 | - |
PE Ratio | 15.43 | 25 | Average PE traded in past 3 years |
Share price | 1196 | 2325 | |
Return | 94% |
Disclaimer: This is a study report, not for any decision making or investment advisory. Invested
Made by: Nidhi Devidan
Date:28th June 2024
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!